Nessi Claudio

CIK 00017220508 companiesST HELIER, Y9

SEC Profile

Transactions

Companies

Filings

CIK

0001722050

Recent Transactions

49 trades

Conversion
Lexeo Therapeutics, Inc.$LXEO
Common Stock
2023-11-07+287,213→ 1,703,078 total
Purchase
Lexeo Therapeutics, Inc.$LXEO
Common Stock
2023-11-07$11.00/sh+454,545→ 2,157,623 total
Conversion
Lexeo Therapeutics, Inc.$LXEO
Common Stock
2023-11-07+1,415,865→ 1,415,865 total
Conversion
Lexeo Therapeutics, Inc.$LXEO
Series A convertible preferred stock
2023-11-07−14,999,999→ 0 total
Conversion
Lexeo Therapeutics, Inc.$LXEO
Series B convertible preferred stock
2023-11-07−2,615,533→ 0 total
Conversion
Theseus Pharmaceuticals, Inc.
Series B Preferred Stock
2021-10-12−693,152→ 0 total
Conversion
Theseus Pharmaceuticals, Inc.
Common Stock
2021-10-12+523,979→ 523,979 total
Purchase
Theseus Pharmaceuticals, Inc.
Common Stock
2021-10-12$16.00/sh+187,500→ 711,479 total
Conversion
Nuvation Bio Inc.$NUVB
Class A Common Stock
2021-02-10+8,130,097→ 27,712,373 total
Award
Nuvation Bio Inc.$NUVB
Class A Common Stock
2021-02-10$10.00/sh+500,000→ 28,212,373 total
Conversion
Nuvation Bio Inc.$NUVB
Series A Preferred Stock
2021-02-10−8,130,097→ 0 total
Conversion
Kronos Bio, Inc.
Common Stock
2020-10-14$16.15/sh+366,299→ 3,368,283 total
Conversion
Kronos Bio, Inc.
Common Stock
2020-10-14+1,606,220→ 1,625,671 total
Conversion
Kronos Bio, Inc.
Series Seed Preferred Stock
2020-10-14−1,522,484→ 0 total
Conversion
Kronos Bio, Inc.
Series A Preferred Stock
2020-10-14−1,304,563→ 0 total
Conversion
Kronos Bio, Inc.
Common Stock
2020-10-14+1,376,313→ 3,001,984 total
Purchase
Kronos Bio, Inc.
Common Stock
2020-10-14$19.00/sh+450,000→ 3,818,283 total
Conversion
Kronos Bio, Inc.
Convertible Promissory Note
2020-10-14→ 0 total
Conversion
Morphic Holding, Inc.
Common Stock
2019-07-01+857,470→ 857,470 total
Conversion
Morphic Holding, Inc.
Common Stock
2019-07-01+1,978,779→ 2,836,249 total
Purchase
Morphic Holding, Inc.
Common Stock
2019-07-01$15.00/sh+133,333→ 2,969,582 total
Conversion
Morphic Holding, Inc.
Series B Preferred Stock
2019-07-01−1,978,779→ 0 total
Conversion
Morphic Holding, Inc.
Series A Preferred Stock
2019-07-01−857,470→ 0 total
Conversion
Translate Bio, Inc.
Common Stock
2018-07-02+979,179→ 979,179 total
Conversion
Translate Bio, Inc.
Common Stock
2018-07-02+1,458,424→ 1,458,424 total
Conversion
Translate Bio, Inc.
Series A Preferred Stock
2018-07-02−2,500,000→ 0 total
Conversion
Translate Bio, Inc.
Series A Preferred Stock
2018-07-02−2,500,000→ 0 total
Conversion
Translate Bio, Inc.
Series B Preferred Stock
2018-07-02−2,000,103→ 0 total
Conversion
Translate Bio, Inc.
Series C Preferred Stock
2018-07-02−302,173→ 0 total
Conversion
Translate Bio, Inc.
Series A Preferred Stock
2018-07-02−5,800,000→ 0 total
Conversion
Translate Bio, Inc.
Series C Preferred Stock
2018-07-02−302,173→ 0 total
Conversion
Translate Bio, Inc.
Common Stock
2018-07-02+979,179→ 979,179 total
Conversion
Translate Bio, Inc.
Common Stock
2018-07-02+1,458,424→ 1,458,424 total
Conversion
Translate Bio, Inc.
Series B Preferred Stock
2018-07-02−1,676,348→ 0 total
Conversion
Translate Bio, Inc.
Series A Preferred Stock
2018-07-02−5,800,000→ 0 total
Conversion
Translate Bio, Inc.
Series B Preferred Stock
2018-07-02−2,000,103→ 0 total
Conversion
Translate Bio, Inc.
Series C Preferred Stock
2018-07-02−1,263,484→ 0 total
Conversion
Translate Bio, Inc.
Series B Preferred Stock
2018-07-02−1,676,348→ 0 total
Conversion
Translate Bio, Inc.
Series C Preferred Stock
2018-07-02−1,263,484→ 0 total
Award
X4 Pharmaceuticals, Inc$XFOR
Stock Option (right to buy)
2018-06-05+10,000→ 10,000 total
Conversion
X4 Pharmaceuticals, Inc$XFOR
Common Stock
2017-11-20+246,682→ 246,682 total
Purchase
X4 Pharmaceuticals, Inc$XFOR
Common Stock
2017-11-20$10.00/sh+300,000→ 867,639 total
Conversion
X4 Pharmaceuticals, Inc$XFOR
Series C Convertible Preferred Stock
2017-11-20−84,040→ 0 total
Conversion
X4 Pharmaceuticals, Inc$XFOR
Common Stock
2017-11-20+41,878→ 288,560 total
Conversion
X4 Pharmaceuticals, Inc$XFOR
Series B Convertible Preferred Stock
2017-11-20−552,487→ 0 total
Conversion
X4 Pharmaceuticals, Inc$XFOR
Series D Convertible Preferred Stock
2017-11-20−952,497→ 0 total
Conversion
X4 Pharmaceuticals, Inc$XFOR
Common Stock
2017-11-20+279,079→ 567,639 total
Award
X4 Pharmaceuticals, Inc$XFOR
Stock Option (right to buy)
2017-11-15+7,324→ 7,324 total
Award
X4 Pharmaceuticals, Inc$XFOR
Common Stock (right to buy)
2017-11-15+25,000→ 25,000 total

Companies

Recent Filings

Address

C/O NEOMED INNOVATION V L.P. 13 CASTLE STREET

ST HELIER, Y9, JE4 5UT

View on SEC.gov